Google
TVGNW Stock Price & Analysis — Tevogen Bio Holdings Inc
TVGNW FAQ
What is TVGNW's ROE?
Tevogen Bio Holdings Inc reports a Return on Equity (ROE) of 216.97%.
What is TVGNW's dividend yield?
Tevogen Bio Holdings Inc offers a dividend yield of 0.00%.
What is TVGNW's Quality Score?
Our AI rates TVGNW's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TVGNW?
Our AI Timing Score for TVGNW is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
TVGNW AI Analysis Summary
Our AI summary for TVGNW: Tevogen Bio Holdings Inc (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of 216.97%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.05
Price
-0.00
(-0.60%)
Day Change
|
|
|---|
TVGNW, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.05 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
0.02 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 15 Independence Boulevard, Warren, NJ, United States, 07059
Phone: 877 838 6436
Website: https://tevogen.com
Sector: -
Description: Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
